Mesoblast submits application for key drug approval
Cellular medicines developer Mesoblast has resubmitted its BLA for approval of Ryoncil (remestemcel-L) in the treatment of children with SR-aGVHD. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. It was only in March that the Food and Drug Administration decided…
